Research programme: chemoprotection - Sound Pharmaceuticals

Drug Profile

Research programme: chemoprotection - Sound Pharmaceuticals

Alternative Names: Allopurinol/ebselen; Chemoprevention research programme - Sound Pharmaceuticals; Chemoprotection research programme - Sound Pharmaceuticals; Ebselen/allopurinol; Research programme: chemoprevention - Sound Pharmaceuticals; SPI-3005/6

Latest Information Update: 30 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sound Pharmaceuticals
  • Class Chemopreventatives; Chemoprotectants; Purines; Small molecules
  • Mechanism of Action Glutathione peroxidase stimulants; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Sensorineural hearing loss

Most Recent Events

  • 30 Nov 2010 Discontinued - Preclinical for Sensorineural hearing loss(chemotherapy-induced, prevention) in USA (PO)
  • 24 Feb 2004 Preclinical trials in Sensorineural hearing loss(chemotherapy-induced, prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top